Friday, February 28, 2020

Why Mascara Makers Will Go Out Of Business Soon

Dr. Alexander Sinclair MD, a famed Beverly Hills, board certified plastic surgeon expects Latisse to become a anchor of eyelash aesthetic remedies in the near future. Latisse is a recent introduction to the world of beauty treatments, and the first FDA-approved product for the growth of upper eyelashes. Regular daily application of Latisse results in the growth of new, darker, thicker eyelashes in 80 percent of the women who use it as prescribed.


Lash magnification is a world known practice dating back to the first dynasty in ancient Egypt (approximately 2920-2770 BCE). Distinguished and affluent citizens applied kohl, a mixture of metal and soot, to lashes and brows to bring distinction to the eyes. Presently, mascara is currently the most common makeup product used by women, according to a 2008 report by NDP, Marketing Group About 83 percent of American women report using mascara, compared with only 64 percent who use lipstick. “A female patient remarked that every woman who uses mascara has been waiting for a product like Latisse,” said Dr, Sinclair. “Most of my patients feel on some level that beautiful lashes are priceless.

“While mascara has served mankind well for many years, Latisse is revolutionary in the sense that it is the first-science based approved product for eyelash growth. Latisse is applied once a day to the eyelid with a disposable applicator. It is applied only to the base of the upper lashes only-not lower lashes-where the eyelash meets the skin of the upper lid. Applications must be made daily to see the effects of Latisse, which begin to appear within 4 to 8 weeks of initial application. Full effects of the Latisse treatment will become visible at 16 weeks after the first use, and can be maintained as long as the regular application is maintained.

Available only by prescription, Dr Alexander Sinclair MD, encourages likely users to call and make an appointment with his office today to see if Latisse is suitable for them.

No comments:

Post a Comment